![Seung Suh Hong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Seung Suh Hong
Directeur/Membre du Conseil chez OCULAR THERAPEUTIX, INC.
Fortune : 50 918 $ au 31/05/2024
Postes actifs de Seung Suh Hong
Sociétés | Poste | Début | Fin |
---|---|---|---|
OCULAR THERAPEUTIX, INC. | Directeur/Membre du Conseil | 11/06/2019 | - |
Independent Dir/Board Member | 11/06/2019 | - | |
Cellemedy Co., Ltd.
![]() Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Directeur des opérations | 01/01/2021 | - |
President | 01/01/2021 | - | |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Directeur/Membre du Conseil | 01/01/2021 | - |
Novelgen Co. Ltd(South Korea) | Directeur/Membre du Conseil | 01/04/2020 | - |
Historique de carrière de Seung Suh Hong
Anciens postes connus de Seung Suh Hong
Sociétés | Poste | Début | Fin |
---|---|---|---|
Celltrion Healthcare Japan KK | President | 01/01/2016 | 02/01/2019 |
CELLTRION HEALTHCARE CO., LTD. | Directeur Général | 01/11/2014 | 01/12/2015 |
Corporate Officer/Principal | 01/04/2002 | 01/11/2014 | |
President | 01/11/2014 | 01/12/2015 |
Formation de Seung Suh Hong
Seoul National University | Doctorate Degree |
Statistiques
Internationale
Corée du Sud | 5 |
Etats-Unis | 2 |
Japon | 2 |
Opérationnelle
Director/Board Member | 3 |
President | 3 |
Independent Dir/Board Member | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
OCULAR THERAPEUTIX, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Celltrion Healthcare Co., Ltd.
![]() Celltrion Healthcare Co., Ltd. Pharmaceuticals: MajorHealth Technology Celltrion Healthcare Co., Ltd. manufactures pharmaceutical products. Its products include infliximab, rituximab, and trastuzumab biosimilars. The company was founded on December 29, 1999 and is headquartered in Incheon, South Korea. | Health Technology |
Celltrion Healthcare Japan KK | |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
Cellemedy Co., Ltd.
![]() Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Commercial Services |
Novelgen Co. Ltd(South Korea) |
- Bourse
- Insiders
- Seung Suh Hong
- Expérience